Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6507760 | 0.83 | TSHR (0.46) | KDM4ETSHRHTTCNR2DPP4 | |
| SCHEMBL6498258 | 0.83 | TSHR (0.46) | KDM4ETSHRHTTCNR2DPP4 | |
| SCHEMBL6500416 | 0.81 | EPHX2 (0.37) | TSHRDPP4EPHX2ALDH1A1 | |
| SCHEMBL6500205 | 0.80 | DPP9 (0.46) | CNR2DPP4ALDH1A1 | |
| SCHEMBL6387572 | 0.78 | ATM (0.35) | KDM4EALDH1A1 | |
| SCHEMBL6426530 | 0.77 | P2RX7 (0.35) | CNR1CNR2EPHX2 | |
| SCHEMBL6510576 | 0.76 | DPP4 (0.52) | MAPTKDM4EHTTCNR2DPP4 | |
| SCHEMBL6500702 | 0.76 | TSHR (0.30) | TSHR | |
| SCHEMBL14532004 | 0.74 | EPHX2 (0.32) | CNR1CNR2EPHX2 | |
| SCHEMBL1386171 | 0.74 | EPHX2 (0.32) | CNR1CNR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
| WO-2005033068-A1 | SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS | OY JUVANTIA PHARMA LTD (FI) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | MAPT 3607/4885KDM4E 2824/4885TSHR 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.